Oritavancin

Against the clinical treatment dilemma of multidrug-resistant Gram-positive bacterial infections, the iterative upgrading of glycopeptide antibiotics has provided better options for clinical practice, and oritavancin is a representative second-generation semi-synthetic lipoglycopeptide antibiotic among them. Its mechanism of action is optimized on the basis of vancomycin. It binds to the D-alanyl-D-alanine terminus of the peptidoglycan precursor of the bacterial cell wall through dual targeting, and anchors to the bacterial cell membrane with the help of lipophilic side chains. The bactericidal activity is significantly enhanced under the dual action, and its half-life is as long as 393 hours, enabling the completion of the treatment course with a single administration. This drug is mainly used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, and has good antibacterial activity against a variety of drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-sensitive enterococci, and Streptococcus pyogenes, especially suitable for infected patients who need to improve medication compliance and reduce hospital stay.

The global market size related to oritavancin has shown a steady growth trend in recent years. In 2023, the overall market size was approximately USD 320 million, with a compound annual growth rate maintained at around 8%. The growth momentum mainly comes from the rising resistance rate of Gram-positive bacteria worldwide and the expansion of demand for outpatient anti-infective treatment. In terms of the competitive landscape, the original research product still occupies the major global market share. At present, the number of approved generic preparations worldwide is very small, the supply of API is highly concentrated, and the overall market competition is relatively low.

The original research enterprise of oritavancin is Merck & Co., Inc. in the United States, and the original brand name is Orbactiv. The expiration date of its core compound patent in the United States is 2024, and the expiration date of the core patent in Europe is 2025. The main dosage form approved by the original research is powder for injection, with a specification of 400 mg per vial. It has been included in the FDA Reference Listed Drug Catalog, and also included in the *Catalogue of Reference Preparations for Chemical Drugs (11th Batch)* of China. Up to now, no enterprise in China has been approved to market oritavancin API, there is no valid A-status registration number on the CDE API registration platform, and no preparation of this variety has been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for oritavancin. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products comply with the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of various stages such as API R&D, quality research, and registration and declaration.